Sirnaomics (2257) investor relations material

Executive summary

• Clinical-stage biopharma focused on siRNA therapeutics, leveraging proprietary delivery platforms for a diversified pipeline in oncology, fibrotic diseases, aesthetics, and metabolic disorders.

• Lead candidate STP705 prioritized for isSCC, advancing to pivotal phase IIb/III trials; STP707 and STP122G progressing in clinical development.

• Strategic restructuring, leadership changes, and cost optimization implemented to enhance operational efficiency, extend financial runway, and prioritize high-value programs.

• No revenue generated; focus remains on R&D and pipeline advancement.

Financial highlights

• Net loss for the six months ended June 30, 2025 was US$3.4 million, a significant decrease from US$43.5 million year-over-year, mainly due to reduced R&D and administrative expenses.

• Administrative expenses decreased 75% to US$2.6 million; R&D expenses down 79% to US$3.0 million.

• Cash and cash equivalents at June 30, 2025 were US$6.9 million, down from US$11.8 million at year-end 2024.

• No product sales revenue; other income decreased 87% to US$0.1 million.

• Positive swing in other gains and losses, mainly from lease modification and asset disposals.

Outlook and guidance

• NDA submission for STP705 targeted as early as 2027, contingent on positive clinical data and regulatory approval.

• Focus on advancing clinical programs, expanding pipeline, and maintaining financial discipline.

• Exploring additional financing, divestment of non-core assets, and strategic partnerships to extend financial runway.

• Continued emphasis on operational agility, cost optimization, and business development to drive sustainable growth.